Stock Events

Stock Events

Search...

Unicycive Therapeutics

$6.96

69

+$0.5+7.74% Friday 00:23

Statistics

Day High

6.96

Day Low

6.96

52W High

-

52W Low

-

Volume

2

Avg. Volume

-

Mkt Cap

149.58M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

19MayExpected

Q3 2025

Next

Next

-0.53

-0.29

-0.05

0.19

Expected EPS

0.194883

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

0Revenue

-75.65MNet Income

Analyst Ratings

$31.00Average Price Target

The highest estimate is 40.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UNCY.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, potentially overlapping with Unicycive's therapeutic areas.

Gilead Sciences

Gilead Sciences competes in the development of innovative therapeutics, including for liver diseases, which may intersect with Unicycive's focus areas.

AbbVie operates in similar therapeutic areas, including renal disease and other serious health conditions, making it a direct competitor.

Amgen focuses on novel therapies for serious illnesses, including kidney diseases, which could compete with Unicycive's product pipeline.

Biomarin Pharmaceutical

BioMarin Pharmaceutical targets rare diseases with its advanced therapies, potentially competing in niche markets targeted by Unicycive.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is involved in developing treatments for serious medical conditions, which may include areas of interest to Unicycive.

Novo Nordisk is a leading company in diabetes care but also explores treatments for other chronic conditions, potentially competing with Unicycive.

Pfizer has a broad portfolio that includes treatments for renal diseases and other areas that could overlap with Unicycive's interests.

AstraZeneca has a diverse portfolio in various therapeutic areas, including those that could compete with Unicycive's focus on kidney diseases.

Merck & Co. is a global healthcare company that develops medicines for a wide range of diseases, some of which may compete with Unicycive's therapies.

About

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Show more...

CEO

ISIN

US90466Y2028

Listings

0 Comments

Share your thoughts

FAQ

What is Unicycive Therapeutics stock price today?▼

The current price of UNCY.BOATS is $6.96 USD — it has increased by +7.74% in the past 24 hours. Watch Unicycive Therapeutics stock price performance more closely on the chart.

What is Unicycive Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Unicycive Therapeutics stocks are traded under the ticker UNCY.BOATS.

What is Unicycive Therapeutics market cap?▼

Today Unicycive Therapeutics has the market capitalization of 149.58M

When is the next Unicycive Therapeutics earnings date?▼

Unicycive Therapeutics is going to release the next earnings report on May 19, 2026.

What is Unicycive Therapeutics revenue for the last year?▼

Unicycive Therapeutics revenue for the last year amounts to 0 USD.

What is Unicycive Therapeutics net income for the last year?▼

UNCY.BOATS net income for the last year is -75.65M USD.

When did Unicycive Therapeutics complete a stock split?▼

Unicycive Therapeutics has not had any recent stock splits.